Open Access
Article
ErbB receptor tyrosine kinase inhibitors as therapeutic agents
Neil G Anderson1,Tawhid Ahmad1
1
Division of Cancer Studies, School of Medicine, University of Manchester, Oxford Road, Manchester M13 9PT, United Kingdom. anderson@man.ac.uk
DOI: 10.2741/anderson Volume 7 Issue 4, pp.1926-1940
Published: 01 September 2002
(This article belongs to the Special Issue Biology and medicine of ErbB tyrosine kinases)
Abstract

The ErbB family of receptor tyrosine kinases comprise four members: EGFR, ErbB2, ErbB3 and ErbB4. All are essential for normal development and participate in the functioning of normal cells. ErbB receptors, particularly EGFR and ErbB2 are commonly deregulated in certain prevalent forms of human cancer. Recently a number of small molecule inhibitors of the tyrosine kinase activity of these receptors have been developed. Some of these agents, known as TKIs, are progressing through clinical trials in patients with aberrant ErbB receptor expression in their tumors. This article provides a brief overview on the structure and biology of ErbB receptors and their ligands before discussing in detail the development and current status of ErbB receptor TKIs. These agents are shown to inhibit multiple features of cancer cells including proliferation, survival, invasion and angiogenesis. It is clear from recent studies that not all cancer cells that overexpress ErbB receptors will be sensitive to TKIs. Potential explanations for resistance to these molecules are reviewed. Finally the prospect of using TKIs in combination with existing chemotherapeutic agents is discussed.

Share and Cite
Neil G Anderson, Tawhid Ahmad. ErbB receptor tyrosine kinase inhibitors as therapeutic agents. Frontiers in Bioscience-Landmark. 2002. 7(4); 1926-1940.